371 related articles for article (PubMed ID: 21128917)
1. Post-kala-azar dermal leishmaniasis--an overview.
Ganguly S; Das NK; Barbhuiya JN; Chatterjee M
Int J Dermatol; 2010 Aug; 49(8):921-31. PubMed ID: 21128917
[TBL] [Abstract][Full Text] [Related]
2. Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis.
Ganguly S; Das NK; Panja M; Pal S; Modak D; Rahaman M; Mallik S; Guha SK; Pramanik N; Goswami R; Barbhuiya JN; Saha B; Chatterjee M
J Infect Dis; 2008 Jun; 197(12):1762-71. PubMed ID: 18444882
[TBL] [Abstract][Full Text] [Related]
3. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
Saha S; Mondal S; Ravindran R; Bhowmick S; Modak D; Mallick S; Rahman M; Kar S; Goswami R; Guha SK; Pramanik N; Saha B; Ali N
J Immunol; 2007 Oct; 179(8):5592-603. PubMed ID: 17911647
[TBL] [Abstract][Full Text] [Related]
4. Interferon (IFN)-gamma , tumor necrosis factor-alpha , interleukin-6, and IFN-gamma receptor 1 are the major immunological determinants associated with post-kala azar dermal leishmaniasis.
Ansari NA; Ramesh V; Salotra P
J Infect Dis; 2006 Oct; 194(7):958-65. PubMed ID: 16960784
[TBL] [Abstract][Full Text] [Related]
5. Enhanced lesional Foxp3 expression and peripheral anergic lymphocytes indicate a role for regulatory T cells in Indian post-kala-azar dermal leishmaniasis.
Ganguly S; Mukhopadhyay D; Das NK; Chaduvula M; Sadhu S; Chatterjee U; Rahman M; Goswami RP; Guha SK; Modak D; Mallik S; Gonju D; Pramanik N; Barbhuiya JN; Saha B; Chatterjee M
J Invest Dermatol; 2010 Apr; 130(4):1013-22. PubMed ID: 20032994
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of serological markers to monitor the disease status of Indian post kala-azar dermal leishmaniasis.
Mukhopadhyay D; Das NK; De Sarkar S; Manna A; Ganguly DN; Barbhuiya JN; Maitra AK; Hazra A; Chatterjee M
Trans R Soc Trop Med Hyg; 2012 Nov; 106(11):668-76. PubMed ID: 22920931
[TBL] [Abstract][Full Text] [Related]
7. Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile.
Ismail A; El Hassan AM; Kemp K; Gasim S; Kadaru AE; Moller T; Kharazmi A; Theander TG
J Pathol; 1999 Dec; 189(4):615-22. PubMed ID: 10629566
[TBL] [Abstract][Full Text] [Related]
8. The pathogenesis of post kala-azar dermal leishmaniasis from the field to the molecule: does ultraviolet light (UVB) radiation play a role?
Ismail A; Khalil EA; Musa AM; El Hassan IM; Ibrahim ME; Theander TG; El Hassan AM
Med Hypotheses; 2006; 66(5):993-9. PubMed ID: 16386855
[TBL] [Abstract][Full Text] [Related]
9. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
[TBL] [Abstract][Full Text] [Related]
10. Post-kala-azar dermal leishmaniasis.
Zijlstra EE; Musa AM; Khalil EA; el-Hassan IM; el-Hassan AM
Lancet Infect Dis; 2003 Feb; 3(2):87-98. PubMed ID: 12560194
[TBL] [Abstract][Full Text] [Related]
11. Genetic heterogeneity among visceral and post-Kala-Azar dermal leishmaniasis strains from eastern India.
Dey A; Singh S
Infect Genet Evol; 2007 Mar; 7(2):219-22. PubMed ID: 17027344
[TBL] [Abstract][Full Text] [Related]
12. Post-kala-azar dermal leishmaniasis: recent developments.
Singh S; Sharma U; Mishra J
Int J Dermatol; 2011 Sep; 50(9):1099-108. PubMed ID: 22126871
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in post-kala-azar dermal leishmaniasis.
Mondal D; Khan MG
Curr Opin Infect Dis; 2011 Oct; 24(5):418-22. PubMed ID: 21885919
[TBL] [Abstract][Full Text] [Related]
14. Challenges in the diagnosis of post kala-azar dermal leishmaniasis.
Salotra P; Singh R
Indian J Med Res; 2006 Mar; 123(3):295-310. PubMed ID: 16778312
[TBL] [Abstract][Full Text] [Related]
15. Visceral Leishmaniasis IgG1 Rapid Monitoring of Cure vs. Relapse, and Potential for Diagnosis of Post Kala-Azar Dermal Leishmaniasis.
Marlais T; Bhattacharyya T; Singh OP; Mertens P; Gilleman Q; Thunissen C; Hinckel BCB; Pearson C; Gardner BL; Airs S; de la Roche M; Hayes K; Hafezi H; Falconar AK; Eisa O; Saad A; Khanal B; Bhattarai NR; Rijal S; Boelaert M; El-Safi S; Sundar S; Miles MA
Front Cell Infect Microbiol; 2018; 8():427. PubMed ID: 30619774
[No Abstract] [Full Text] [Related]
16. Evidence for involvement of Th17 type responses in post kala azar dermal leishmaniasis (PKDL).
Katara GK; Ansari NA; Singh A; Ramesh V; Salotra P
PLoS Negl Trop Dis; 2012; 6(6):e1703. PubMed ID: 22724038
[TBL] [Abstract][Full Text] [Related]
17. The importance of T cell-derived cytokines in post-kala-azar dermal leishmaniasis.
Jafarzadeh A; Jafarzadeh S; Sharifi I; Aminizadeh N; Nozari P; Nemati M
Cytokine; 2021 Nov; 147():155321. PubMed ID: 33039255
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of cellular immunological responses in mono- and polymorphic clinical forms of post-kala-azar dermal leishmaniasis in India.
Kaushal H; Bras-Gonçalves R; Avishek K; Kumar Deep D; Petitdidier E; Lemesre JL; Papierok G; Kumar S; Ramesh V; Salotra P
Clin Exp Immunol; 2016 Jul; 185(1):50-60. PubMed ID: 26948150
[TBL] [Abstract][Full Text] [Related]
19. Use of rK39 for diagnosis of post kala-azar dermal leishmaniasis in Nepal.
Das ML; Deb M; Karki BM; Sarif M; Khanal B; Bhattacharya SK; Agrawal S; Koirala S
Southeast Asian J Trop Med Public Health; 2007 Jul; 38(4):619-25. PubMed ID: 17882997
[TBL] [Abstract][Full Text] [Related]
20. The immunology of post-kala-azar dermal leishmaniasis (PKDL).
Zijlstra EE
Parasit Vectors; 2016 Aug; 9(1):464. PubMed ID: 27553063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
